GSK (NYSE:GSK) Shares Acquired Rep. Bruce Westerman

Representative Bruce Westerman (R-Arkansas) recently bought shares of GSK plc NYSE: GSK. In a filing disclosed on April 16th, the Representative disclosed that they had bought between $1,001 and $15,000 in GSK stock on March 3rd. The trade occurred in the Representative's "FISHER IRA" account.

Representative Bruce Westerman also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of LVMH Moët Hennessy - Louis Vuitton, Société Européenne OTCMKTS: LVMUY on 4/2/2025.
• Purchased $1,001 - $15,000 in shares of Sony Group NYSE: SONY on 3/24/2025.
• Purchased $1,001 - $15,000 in shares of Mitsubishi UFJ Financial Group NYSE: MUFG on 3/21/2025.
• Purchased $1,001 - $15,000 in shares of BP NYSE: BP on 3/21/2025.
• Sold $1,001 - $15,000 in shares of Procter & Gamble NYSE: PG on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Medtronic NYSE: MDT on 3/20/2025.
• Purchased $1,001 - $15,000 in shares of ASML NASDAQ: ASML on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 3/20/2025.

GSK Trading Up 0.7 %

NYSE GSK traded up $0.27 during trading hours on Wednesday, hitting $36.90. 3,179,629 shares of the company's stock were exchanged, compared to its average volume of 4,676,717. The business's 50 day moving average is $37.44 and its 200-day moving average is $36.06. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. GSK plc has a 12-month low of $31.72 and a 12-month high of $45.93. The firm has a market capitalization of $76.13 billion, a P/E ratio of 23.21, a price-to-earnings-growth ratio of 1.12 and a beta of 0.56.

GSK (NYSE:GSK - Get Free Report) last released its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. As a group, analysts anticipate that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, April 10th. Stockholders of record on Friday, February 21st were issued a dividend of $0.3932 per share. This is a boost from GSK's previous quarterly dividend of $0.39. The ex-dividend date was Friday, February 21st. This represents a $1.57 annualized dividend and a dividend yield of 4.26%. GSK's dividend payout ratio (DPR) is 100.63%.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on GSK. BNP Paribas started coverage on shares of GSK in a research note on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price objective on the stock. Morgan Stanley started coverage on GSK in a research report on Wednesday, February 12th. They set an "equal weight" rating on the stock. Finally, StockNews.com downgraded shares of GSK from a "strong-buy" rating to a "buy" rating in a report on Wednesday, April 16th. Eight equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $40.58.

Institutional Trading of GSK

Several institutional investors have recently made changes to their positions in GSK. Dodge & Cox grew its holdings in GSK by 0.5% in the 4th quarter. Dodge & Cox now owns 68,440,912 shares of the pharmaceutical company's stock valued at $2,314,672,000 after buying an additional 353,749 shares during the last quarter. FMR LLC increased its holdings in GSK by 82.1% during the 4th quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company's stock valued at $1,786,475,000 after purchasing an additional 23,814,104 shares in the last quarter. Primecap Management Co. CA raised its holdings in shares of GSK by 70.1% in the fourth quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company's stock valued at $854,349,000 after buying an additional 10,407,905 shares during the last quarter. Fisher Asset Management LLC raised its stake in shares of GSK by 1.4% in the fourth quarter. Fisher Asset Management LLC now owns 18,836,797 shares of the pharmaceutical company's stock worth $637,061,000 after acquiring an additional 259,867 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in GSK by 0.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,566,922 shares of the pharmaceutical company's stock worth $255,914,000 after buying an additional 35,134 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

About Representative Westerman

Bruce Westerman (Republican Party) is a member of the U.S. House, representing Arkansas' 4th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027. Westerman (Republican Party) is running for re-election to the U.S. House to represent Arkansas' 4th Congressional District. He declared candidacy for the 2026 election. Westerman earned his BSBAGE in biological and agricultural engineering from the University of Arkansas in 1990 and his MF in forestry from Yale University in 2001. His professional experience includes working as a plant engineer for Riceland Foods and an engineer/forester for Mid-South Engineering Company.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.